Equillium EQ 深 滬
已收盤 02-06 16:00:00 美东时间
1.52
+0.040
+2.70%
華盛通- 最 高1.6055
- 今 開1.49
- 成交量 74.27万股
- 最 低 1.49
- 昨 收 1.48
- 總市值 9255.78万
- 52周最高 2.35
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 0.27
- 委 比 90.83%
- 總股本 6089.33万
- 歷史最高 27.05
- 量 比 1.04
- 振 幅 7.80%
- 歷史最低 0.27
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Equillium Grants Stock Options to New Employees Under 2024 Inducement Plan
Equillium Grants Stock Options to New Employees Under 2024 Inducement Plan Equillium Inc. announced that its Board of Directors granted inducement awards of nonstatutory stock options to purchase a total of 59,750 shares of common stock to two new employees under the company's 2024 Inducement Plan.
02-03 05:05
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium, a biotech company developing novel therapies for severe autoimmune and inflammatory disorders, granted 59,750 nonstatutory stock options to two new employees under its 2024 Inducement Plan on January 30, 2026. The options have an exercise price of $1.42 per share and vest over four years, with 25% vesting after one year and the rest vesting monthly over 36 months. Equillium focuses on EQ504, a potent aryl hydrocarbon receptor modulator...
02-02 21:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Equillium to Participate in Upcoming Investor Conferences
Equillium, a clinical-stage biotech company focused on developing therapies for severe autoimmune and inflammatory disorders, announced that its management will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 11:30 AM EST, and the Evercore ISI 8th Annual Healthcare Conference on December 3, 2025, at 3:50 PM EST. Both events will feature fireside chats and one-on-one meetings. Investors can review the com...
2025-11-20 21:35
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
- Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027. - Hosted KOL event highlighting AhR's role in UC and potential of EQ504, a novel oral AhR modulator. - EQ504 Phase 1 clinical study initiation planned for mid-2026. - Third quarter 2025 financial results: Revenue of $0, R&D expenses of $1.3 million, G&A expenses of $3.3 million, net loss of $4.2 million, and cash of $33.1 million. - About EQ5...
2025-11-13 21:05
Equillium to Participate in Upcoming Investor Conferences
Equillium Inc. announced that its management will participate in the Stifel Healthcare Conference on November 12, 2025, with a presentation and one-on-one meetings, and the Jefferies Global Healthcare Conference in London from November 18–20, 2025, focusing on one-on-one investor meetings. These events allow investors to engage with Equillium’s leadership, and a live webcast of the Stifel presentation will be available on the company’s Events & P...
2025-11-04 13:30
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. announced that its Compensation Committee granted inducement awards of nonstatutory stock options to purchase 7,200 shares of common stock to a new employee under the 2024 Inducement Plan. The stock options, with an exercise price of $1.41 per share, will vest over four years, with 25% vesting after one year and the remainder monthly over the following 36 months. The company is developing EQ504, an aryl hydrocarbon receptor modula...
2025-11-03 21:05
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Equillium, a biotech company, will host a virtual KOL event on November 5, 2025, to discuss unmet needs in ulcerative colitis (UC) and the potential of targeting AhR for inflammation resolution and mucosal healing. Experts Francisco J. Quintana, PhD, and Brian Feagan, MD, will speak, followed by a presentation on EQ504, Equillium's AhR modulator. EQ504 activates anti-inflammatory and regenerative pathways, with preclinical data showing enhanced I...
2025-10-22 12:00
Equillium Announces Leadership and Corporate Updates
Equillium Inc. announced updates to its Board of Directors and senior leadership, including promoting Dr. Stephen Connelly to President and CEO Bruce Steel remaining in his role. Dr. Bala Manian and Dr. Stephen Connelly resigned from the Board, while Daniel M. Bradbury became Chairman. The company also terminated its agreement with Biocon related to itolizumab. Equillium is focusing on advancing EQ504, its novel AhR modulator, for severe inflamma...
2025-10-06 20:02
